Search

Search Constraints

You searched for: Author/Creator Fruchart, C.

Search Results

1. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. (12th June 2019)

2. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. (June 2017)

3. REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH‐RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R‐CHOP. (June 2017)

4. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. (June 2017)

5. P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE. (23rd June 2022)

6. IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY. (June 2017)

7. LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY. (June 2017)